12,172 Shares in Sanofi (NASDAQ:SNY) Acquired by Meriwether Wealth & Planning LLC

Meriwether Wealth & Planning LLC bought a new position in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,172 shares of the company’s stock, valued at approximately $587,000.

A number of other large investors have also recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new position in Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Sierra Ocean LLC acquired a new position in Sanofi in the fourth quarter valued at approximately $44,000. Finally, Versant Capital Management Inc acquired a new position in Sanofi in the fourth quarter valued at approximately $54,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $59.25 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a fifty day moving average price of $52.65 and a 200 day moving average price of $52.73. Sanofi has a 1-year low of $45.22 and a 1-year high of $59.72. The company has a market cap of $150.37 billion, a PE ratio of 23.80, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on SNY shares. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.